Kazia Therapeutics (ASX:KZA) has entered into a worldwide exclusive licensing agreement and a master services agreement with European company Evotec SE for EVT801, a small molecule, first-in-class oncology drug candidate.
Read more:
https://biotechdispatch.com.au/news/kazia-licenses-global-rights
